Pharmafile Logo

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

November 19, 2015 |  

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Data presented during ACR 2015 highlighted the potential impact the Janus kinase inhibitors (JAKi) will bring to optimising treatment for rheumatoid arthritis patients. Read more here http://goo.gl/djQAML- PMLiVE

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid Group’s new website is launched!

Lucid Group unveil new website...

He who dares wins

The benefits of including medical experts in your brand planning team

Does your medical education drive change in clinical practice?

How to advance outcomes for patients using a medical education process, by Jan Steele PhD, operations director, Lucid

Advance the way you work with your experts

Written by Jan Steele PhD, operations director, Lucid